VolitionRX

VNRX

Market cap $40.9M

HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind Global Asset Management XII LLC (the "Investor"), an investment fund managed by The Lind Partners, a New York-based institutional fund manager.

Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1.

HENDERSON, Nev. , Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.

HENDERSON, Nev. , Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled " Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy ".

HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently.

HENDERSON, Nev. , Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis.

HENDERSON, Nev. , Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.

VolitionRx Limited ( VNRX ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Louise Batchelor Day - Group Chief Marketing & Communications Officer Cameron Reynolds - Founder, CEO, President & Director Jacob Micallef - Chief Scientific Officer Terig Hughes - CFO & Treasurer Conference Call Participants Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Steven Ralston - Zacks Investment Research, Inc. Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.

Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada , Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025.

Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.